Survival Estimation, Prognostic Factors Evaluation, and Prognostic Prediction Nomogram Construction of Breast Cancer Patients with Bone Metastasis in the Department of Bone and Soft Tissue Tumor: A Single Center Experience of 8 Years in Tianjin, China

Table 1

Demographic and clinicopathologic characteristics in the present study.

Subject characteristics	Total cohort	Construction cohort	Validation cohort	χ^2	value
	N (%)	N (%)	N (%)
Age
18–45	134 (39.1)	98 (40.3)	36 (36.0)	0.594	0.743
46–55	109 (31.8)	75 (30.9)	34 (34.0)
>55	100 (29.2)	70 (28.8)	30 (30.0)
Marital status
Married	324 (94.5)	228 (93.8)	96 (96.0)	0.639	0.424
Unmarried	19 (5.5)	15 (6.2)	4 (4.0)
History of smoking
Yes	17 (5.0)	11 (4.5)	6 (6.0)	0.326	0.568
No	326 (95.0)	232 (95.5)	94 (94.0)
Alcohol consumption
Yes	14 (4.1)	12 (4.9)	2 (2.0)	1.562	0.211
No	329 (95.9)	231 (95.1)	98 (98.0)
Menstrual status
Menstruation	108 (31.5)	80 (32.9)	28 (28.0)	0.796	0.372
Menopause	235 (68.5)	163 (67.1)	72 (72.0)
History of abortion
No	236 (68.8)	162 (66.7)	74 (74.0)	1.775	0.183
Yes	107 (31.2)	81 (33.3)	26 (26.0)
Family history of tumor
Yes	83 (24.2)	61 (25.1)	22 (22.0)	0.372	0.542
No	260 (75.8)	182 (74.9)	78 (78.0)
ABO blood type
A type	90 (26.2)	66 (27.2)	24 (24.0)	0.549	0.908
B type	116 (33.8)	82 (33.7)	34 (34.0)
AB type	46 (13.4)	31 (12.8)	15 (15.0)
O type	91 (26.5)	64 (26.3)	27 (27.0)
HGB
115–150 g/L	276 (80.5)	194 (79.8)	82 (82.0)	0.227	0.893
<115 g/L	59 (17.2)	43 (17.7)	16 (16.0)
>150 g/L	8 (2.3)	6 (2.5)	2 (2.0)
CA153
0–25 U/ml	113 (32.9)	75 (30.9)	38 (38.0)	1.633	0.201
>25 U/ml	230 (67.1)	168 (69.1)	62 (62.0)
CEA
0–5 ng/ml	171 (49.9)	116 (47.7)	55 (55.0)	1.495	0.221
>5 ng/ml	172 (50.1)	127 (52.3)	45 (45.0)
ALP
50–135 U/L	227 (66.2)	164 (67.5)	63 (63.0)	0.659	0.719
<50 U/L	26 (7.6)	18 (7.4)	8 (8.0)
>135 U/L	90 (26.2)	61 (25.1)	29 (29.0)
Serum calcium
2.10–2.55 mmol/L	228 (66.5)	165 (67.9)	63 (63.0)	1.050	0.592
<2.10 mmol/L	38 (11.1)	27 (11.1)	11 (11.0)
>2.55 mmol/L	77 (22.4)	51 (21.0)	26 (26.0)
Pathology
Ductal carcinoma	219 (63.8)	155 (63.8)	64 (64.0)	0.001	0.970
Others	124 (36.2)	88 (36.2)	36 (36.0)
Grade
I-II	238 (69.4)	172 (70.8)	66 (66.0)	0.763	0.382
III	105 (30.6)	71 (29.2)	34 (34.0)
Tumor size
<2 cm	123 (35.9)	80 (32.9)	43 (43.0)	3.187	0.203
2–5 cm	175 (51.0)	129 (53.1)	46 (46.0)
>5 cm	45 (13.1)	34 (14)	11 (11.0)
Lymph node metastasis
Yes	276 (80.5)	198 (81.5)	78 (78.0)	0.546	0.460
No	67 (19.5)	45 (18.5)	22 (22.0)
ER status
Positive	237 (69.1)	165 (67.9)	72 (72.0)	0.557	0.455
Negative	106 (30.9)	78 (32.1)	28 (28.0)
PR status
Positive	194 (56.6)	134 (55.1)	60 (60.0)	0.680	0.410
Negative	149 (43.4)	109 (44.9)	40 (40.0)
Her-2 status
Positive	74 (21.6)	51 (21.0)	23 (23.0)	0.170	0.681
Negative	269 (78.4)	192 (79.0)	77 (77.0)
Ki-67 status
Positive	87 (25.4)	60 (24.7)	27 (27.0)	0.199	0.655
Negative	256 (74.6)	183 (75.3)	73 (73.0)
Surgery for BC
Yes	262 (76.4)	186 (76.5)	76 (76.0)	0.012	0.914
No	81 (23.6)	57 (23.5)	24 (24.0)
Chemotherapy
No	21 (6.1)	11 (4.5)	10 (10.0)	3.692	0.055
Yes	322 (93.9)	232 (95.5)	90 (90.0)
Radiotherapy
No	225 (65.6)	160 (65.8)	65 (65.0)	0.022	0.881
Yes	118 (34.4)	83 (34.2)	35 (35.0)
Endocrinotherapy
No	183 (53.4)	129 (53.1)	54 (54.0)	0.024	0.878
Yes	160 (46.6)	114 (46.9)	46 (46.0)
Targeted therapy
No	302 (88.0)	212 (87.2)	90 (90.0)	0.512	0.474
Yes	41 (12.0)	31 (12.8)	10 (10.0)
Time of BM
SBM	148 (43.1)	104 (42.8)	44 (44.0)	0.042	0.838
MBM	195 (56.9)	139 (57.2)	56 (56.0)
Radiotherapy for BM
No	283 (82.5)	202 (83.1)	81 (81.0)	0.222	0.637
Yes	60 (17.5)	41 (16.9)	19 (19.0)
Pathological fracture
No	310 (90.4)	222 (91.4)	88 (88.0)	0.919	0.338
Yes	33 (9.6)	21 (8.6)	12 (12.0)
Spinal cord compression
No	333 (97.1)	236 (97.1)	97 (97.0)	0.004	0.952
Yes	10 (2.9)	7 (2.9)	3 (3.0)
Surgery for BM
No	334 (97.4)	237 (97.5)	97 (97.0)	0.078	0.780
Yes	9 (2.6)	6 (2.5)	3 (3.0)
Performance of BPs
No	84 (24.5)	56 (23.0)	28 (28.0)	0.941	0.332
Yes	259 (75.5)	187 (77.0)	72 (72.0)
Liver metastasis
No	224 (65.3)	155 (63.8)	69 (69.0)	0.850	0.357
Yes	119 (34.7)	88 (36.2)	31 (31.0)
Brain metastasis
No	307 (89.5)	217 (89.3)	90 (90.0)	0.037	0.848
Yes	36 (10.5)	26 (10.7)	10 (10.0)
Lung metastasis
No	206 (60.1)	147 (60.5)	59 (59.0)	0.066	0.797
Yes	137 (39.9)	96 (39.5)	41 (41.0)
Other organs metastasis
No	267 (77.8)	191 (78.6)	76 (76.0)	0.278	0.598
Yes	76 (22.2)	52 (21.4)	24 (24.0)

HGB: hemoglobin; CA153: carbohydrate antigen 153; CEA: carcinoembryonic antigen; ALP: alkaline phosphatase; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2; BC: breast cancer; BM: bone metastasis; SBM: synchronous bone metastasis; MBM: metachronous bone metastasis; BPs: bisphosphonates.